Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 29CNS 13Genitourinary 12Gastrointestinal 10Lymphoid 9Myeloid 7Endocrine 4Dermatologic 4Head & Neck 2Plasma cell 1Other hematologic neoplasm 1NET 1Gynecologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 73Carcinoma, Non-Small-Cell Lung 34Thyroid Neoplasms 29Melanoma 26Ovarian Neoplasms 25Mouth Neoplasms 23Colorectal Neoplasms 20Oropharyngeal Neoplasms 19Breast Neoplasms 18Uterine Cervical Neoplasms 16Carcinoma, Squamous Cell 16Nasopharyngeal Carcinoma 15Lung Neoplasms 15Carcinoma, Renal Cell 15Neoplasm Metastasis 14Urinary Bladder Neoplasms 13Stomach Neoplasms 13Sarcoma 13Laryngeal Neoplasms 13Triple Negative Breast Neoplasms 12Prostatic Neoplasms 12Carcinoma 12Esophageal Neoplasms 11Endometrial Neoplasms 11Neoplasms 10Pancreatic Neoplasms 9Hypopharyngeal Neoplasms 9Salivary Gland Neoplasms 8Carcinoma, Transitional Cell 7

Interventions

tipifarnib 1fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteosarcoma × Head & Neck × 30 days × Clear all
NCT04284774 2026-05-27

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Wilms Tumor, Neuroblastoma, Pheochromocytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Thyroid Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡